While peptide-based vaccines are highly specific and can be tailored to target mutations or overexpressed proteins in cancer cells, their efficacy can be limited by MHC diversity and potential tumor antigen escape.396,399 DC vaccines involve extracting dendritic cells from the patient, loading them with tumor antigens in vitro, and reinfusing them. Here, HLA-C is linked to cancer.